CA1053548A - Methode et reactifs pour reduire les erreurs dans les dosages enzymatiques - Google Patents
Methode et reactifs pour reduire les erreurs dans les dosages enzymatiquesInfo
- Publication number
- CA1053548A CA1053548A CA314,224A CA314224A CA1053548A CA 1053548 A CA1053548 A CA 1053548A CA 314224 A CA314224 A CA 314224A CA 1053548 A CA1053548 A CA 1053548A
- Authority
- CA
- Canada
- Prior art keywords
- reagent
- concentration
- nad
- assay
- glucose
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 239000003153 chemical reaction reagent Substances 0.000 title claims abstract description 44
- 238000007824 enzymatic assay Methods 0.000 title claims description 6
- 238000000034 method Methods 0.000 title abstract description 9
- BAWFJGJZGIEFAR-NNYOXOHSSA-N NAD zwitterion Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-N 0.000 claims abstract description 27
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 claims abstract description 27
- 229950006238 nadide Drugs 0.000 claims abstract description 26
- 102000004420 Creatine Kinase Human genes 0.000 claims abstract description 17
- 108010042126 Creatine kinase Proteins 0.000 claims abstract description 17
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims abstract description 17
- 239000008103 glucose Substances 0.000 claims abstract description 17
- SOWBFZRMHSNYGE-UHFFFAOYSA-N oxamic acid Chemical class NC(=O)C(O)=O SOWBFZRMHSNYGE-UHFFFAOYSA-N 0.000 claims abstract description 9
- 150000003839 salts Chemical class 0.000 claims abstract description 7
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 claims description 21
- ZKHQWZAMYRWXGA-KQYNXXCUSA-J ATP(4-) Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-J 0.000 claims description 11
- ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 claims description 11
- DRBBFCLWYRJSJZ-UHFFFAOYSA-N N-phosphocreatine Chemical compound OC(=O)CN(C)C(=N)NP(O)(O)=O DRBBFCLWYRJSJZ-UHFFFAOYSA-N 0.000 claims description 10
- 230000000694 effects Effects 0.000 claims description 8
- 150000001875 compounds Chemical class 0.000 claims description 7
- 102000005548 Hexokinase Human genes 0.000 claims description 5
- 108700040460 Hexokinases Proteins 0.000 claims description 5
- 239000000203 mixture Substances 0.000 claims description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 5
- 102100031126 6-phosphogluconolactonase Human genes 0.000 claims description 4
- 108010029731 6-phosphogluconolactonase Proteins 0.000 claims description 4
- 108010018962 Glucosephosphate Dehydrogenase Proteins 0.000 claims description 4
- 235000006408 oxalic acid Nutrition 0.000 claims description 4
- 159000000003 magnesium salts Chemical class 0.000 claims description 3
- 239000007787 solid Substances 0.000 claims description 3
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 abstract description 23
- 238000003556 assay Methods 0.000 abstract description 17
- 238000006243 chemical reaction Methods 0.000 abstract description 15
- BOPGDPNILDQYTO-NNYOXOHSSA-N nicotinamide-adenine dinucleotide Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 BOPGDPNILDQYTO-NNYOXOHSSA-N 0.000 abstract description 14
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 abstract description 10
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 abstract description 7
- 101710088194 Dehydrogenase Proteins 0.000 abstract description 6
- 229910021529 ammonia Inorganic materials 0.000 abstract description 5
- 239000000470 constituent Substances 0.000 abstract description 3
- 230000008034 disappearance Effects 0.000 abstract description 3
- 108010021582 Glucokinase Proteins 0.000 abstract description 2
- 238000005259 measurement Methods 0.000 abstract description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 abstract 1
- 229940101270 nicotinamide adenine dinucleotide (nad) Drugs 0.000 abstract 1
- 239000000523 sample Substances 0.000 description 12
- NBSCHQHZLSJFNQ-GASJEMHNSA-N D-Glucose 6-phosphate Chemical compound OC1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H](O)[C@H]1O NBSCHQHZLSJFNQ-GASJEMHNSA-N 0.000 description 8
- VFRROHXSMXFLSN-UHFFFAOYSA-N Glc6P Natural products OP(=O)(O)OCC(O)C(O)C(O)C(O)C=O VFRROHXSMXFLSN-UHFFFAOYSA-N 0.000 description 8
- XTWYTFMLZFPYCI-KQYNXXCUSA-N 5'-adenylphosphoric acid Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O XTWYTFMLZFPYCI-KQYNXXCUSA-N 0.000 description 7
- XTWYTFMLZFPYCI-UHFFFAOYSA-N Adenosine diphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(O)=O)C(O)C1O XTWYTFMLZFPYCI-UHFFFAOYSA-N 0.000 description 7
- CVSVTCORWBXHQV-UHFFFAOYSA-N creatine Chemical compound NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 description 5
- 229910019142 PO4 Inorganic materials 0.000 description 4
- 239000010452 phosphate Substances 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 238000002835 absorbance Methods 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 230000002255 enzymatic effect Effects 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- BIRSGZKFKXLSJQ-SQOUGZDYSA-N 6-Phospho-D-gluconate Chemical compound OP(=O)(O)OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O BIRSGZKFKXLSJQ-SQOUGZDYSA-N 0.000 description 2
- BAWFJGJZGIEFAR-NNYOXOHSSA-O NAD(+) Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-O 0.000 description 2
- XJLXINKUBYWONI-DQQFMEOOSA-N [[(2r,3r,4r,5r)-5-(6-aminopurin-9-yl)-3-hydroxy-4-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2s,3r,4s,5s)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphate Chemical compound NC(=O)C1=CC=C[N+]([C@@H]2[C@H]([C@@H](O)[C@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-DQQFMEOOSA-N 0.000 description 2
- 239000012190 activator Substances 0.000 description 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 229960003624 creatine Drugs 0.000 description 2
- 239000006046 creatine Substances 0.000 description 2
- IRXRGVFLQOSHOH-UHFFFAOYSA-L dipotassium;oxalate Chemical compound [K+].[K+].[O-]C(=O)C([O-])=O IRXRGVFLQOSHOH-UHFFFAOYSA-L 0.000 description 2
- VIKNJXKGJWUCNN-XGXHKTLJSA-N norethisterone Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 VIKNJXKGJWUCNN-XGXHKTLJSA-N 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- JVTAAEKCZFNVCJ-REOHCLBHSA-M (S)-lactate Chemical compound C[C@H](O)C([O-])=O JVTAAEKCZFNVCJ-REOHCLBHSA-M 0.000 description 1
- 229930024421 Adenine Natural products 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- 101100536354 Drosophila melanogaster tant gene Proteins 0.000 description 1
- 101100091152 Mus musculus Rnf41 gene Proteins 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- VFRROHXSMXFLSN-KCDKBNATSA-N aldehydo-D-galactose 6-phosphate Chemical compound OP(=O)(O)OC[C@@H](O)[C@H](O)[C@H](O)[C@@H](O)C=O VFRROHXSMXFLSN-KCDKBNATSA-N 0.000 description 1
- 230000008033 biological extinction Effects 0.000 description 1
- 239000012472 biological sample Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 239000005515 coenzyme Substances 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- VHJLVAABSRFDPM-ZXZARUISSA-N dithioerythritol Chemical compound SC[C@H](O)[C@H](O)CS VHJLVAABSRFDPM-ZXZARUISSA-N 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 150000004715 keto acids Chemical class 0.000 description 1
- 229940116871 l-lactate Drugs 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000003405 preventing effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
Landscapes
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US05/465,039 US3956069A (en) | 1974-04-29 | 1974-04-29 | Enzymatic assays for glucose, creatine phosphokinase or plasma ammonia |
| CA220,039A CA1051326A (fr) | 1974-04-29 | 1975-02-13 | Methode et reactif pour eliminer les erreurs dans les epreuves avec des enzymes |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA1053548A true CA1053548A (fr) | 1979-05-01 |
Family
ID=25667828
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA314,224A Expired CA1053548A (fr) | 1974-04-29 | 1978-10-25 | Methode et reactifs pour reduire les erreurs dans les dosages enzymatiques |
Country Status (1)
| Country | Link |
|---|---|
| CA (1) | CA1053548A (fr) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113075139A (zh) * | 2021-03-29 | 2021-07-06 | 迪瑞医疗科技股份有限公司 | 一种稳定的双试剂血氨测定试剂盒 |
-
1978
- 1978-10-25 CA CA314,224A patent/CA1053548A/fr not_active Expired
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113075139A (zh) * | 2021-03-29 | 2021-07-06 | 迪瑞医疗科技股份有限公司 | 一种稳定的双试剂血氨测定试剂盒 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US3956069A (en) | Enzymatic assays for glucose, creatine phosphokinase or plasma ammonia | |
| EP0973938B1 (fr) | Utilisation des analogues des nadph et nadh pour mesurer les activites enzymatiques et les metabolites | |
| US4242446A (en) | Method for determining a substance in a biological fluid and reagent combination for use in the method | |
| US3764478A (en) | Stabilized enzymatic test reagents | |
| EP0794260B1 (fr) | Réactif bioluminiscent et méthode pour la détermination quantitative d'esters phosphatiques de l'adénosine en employant ce réactif | |
| Dodgson et al. | Inhibition of CA V decreases glucose synthesis from pyruvate | |
| US4271264A (en) | Stabilized liquid enzyme and coenzyme compositions | |
| US4357420A (en) | Bioluminescence methods for enzymatic determinations | |
| US4277562A (en) | Stabilized liquid enzyme and coenzyme compositions | |
| GB2055200A (en) | Enhancement of the sensitivity of bioluminescent and chemiluminescent assays with enzymatic cycling | |
| US5334507A (en) | Composition for measurement of potassium ion concentration and composition for elimination of ammonium ions | |
| US5278044A (en) | Stable aqueous NADH reagent and kit | |
| US4742001A (en) | Method of terminating isocitrate dehydrogenase reaction in an analytical system | |
| US5460948A (en) | Assay of salicylates or reduced pyridine nucleotides | |
| CA1053548A (fr) | Methode et reactifs pour reduire les erreurs dans les dosages enzymatiques | |
| US3974037A (en) | Process for measuring carbon dioxide content of the body fluid | |
| US3331752A (en) | Determination of dehydrogenase | |
| US3335069A (en) | Composition and method for determining uric acid | |
| US5589348A (en) | In situ nicotinamide coenzyme generating system for enzyme based clinical chemistry assays | |
| US4206280A (en) | Determination of acid phosphatase | |
| EP0207493B1 (fr) | Procédé pour terminer la réaction de la isocitrate-déshydrogénase | |
| US5250416A (en) | Method for highly sensitive determination of NADH using kinase | |
| US20020068310A1 (en) | Method and reagant for quantitative determination of 1,5-anhydroglucitol | |
| US5206135A (en) | Use of the oxygenase activity of acetolactate synthase for herbicide detection | |
| US5258286A (en) | Method of terminating isocitrate dehydrogenase reaction |